Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26814535 | 1.00 | SLC6A3 (0.33) | SLC6A3CYP1A2SIGMAR1 | |
| SCHEMBL14664303 | 1.00 | SLC6A3 (0.33) | SLC6A3CYP1A2SIGMAR1 | |
| SCHEMBL14156564 | 0.87 | CYP1A2 (0.35) | CYP1A2 | |
| SCHEMBL6245124 | 0.82 | S1PR1 (0.40) | SIGMAR1 | |
| SCHEMBL90077 | 0.81 | KAT6A (0.32) | — | |
| SCHEMBL14948548 | 0.81 | KAT6A (0.32) | — | |
| SCHEMBL14948558 | 0.81 | KAT6A (0.32) | — | |
| SCHEMBL10486835 | 0.80 | NCF1 (0.37) | CYP1A2 | |
| SCHEMBL1183788 | 0.80 | SIGMAR1 (0.45) | SIGMAR1 | |
| SCHEMBL13555595 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| WO-2023073115-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-04 | — | — | WO | disclosed |
| US-9895443-B2 | Multi-tailed lipids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-02-20 | — | — | US | disclosed |
| EP-2900672-B1 | BET-PROTEIN INHIBITORY 5-ARYL-TRIAZOLO-AZEPINES | Bayer Pharma AG (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2235012-B1 | 4-AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | PALAU PHARMA SA (ES) | 2013-07-17 | — | — | EP | disclosed |
| EP-1795527-B1 | CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-7405217-B2 | N-aroyl piperazine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-07-29 | — | — | US | disclosed |
| US-20070167457-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC | 2007-07-19 | — | — | US | disclosed |
| US-7166608-B2 | N-aroyl piperazine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-23 | — | — | US | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | SLC6A3 1471/4885CYP1A2 1431/4885SIGMAR1 4381/4885 |
| US-20070167457-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | SLC6A3 604/4885CYP1A2 2058/4885SIGMAR1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.